+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
DNA Repair Drugs Market by Drug Class, Mechanism of Action, Indication, Route of Administration, End User - Global Forecast to 2030- Product Image
DNA Repair Drugs Market by Drug Class, Mechanism of Action, Indication, Route of Administration, End User - Global Forecast to 2030- Product Image
Sale

DNA Repair Drugs Market by Drug Class, Mechanism of Action, Indication, Route of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977983
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The DNA Repair Drugs Market is experiencing rapid transformation, driven by cutting-edge advances in drug development and emerging therapeutic strategies. This evolving sector intersects oncology innovation, rare disease research, and global regulatory dynamics, presenting distinct opportunities and challenges for senior decision-makers seeking sustained growth and market leadership.

Market Snapshot: DNA Repair Drugs Market

The DNA Repair Drugs Market grew from USD 9.18 billion in 2024 to USD 9.87 billion in 2025. It is expected to continue growing at a CAGR of 7.25%, reaching USD 13.98 billion by 2030. This upward trajectory is underpinned by surging clinical interest in therapies that restore genomic integrity, the introduction of improved molecular targets, and increasing collaboration between academic, pharmaceutical, and contract research organizations globally. Synthetic lethality and combination regimens hold significant promise for enhancing cancer care and expanding therapeutic applications, and the market is adapting to supply chain challenges brought on by macroeconomic and policy changes.

Scope & Segmentation

  • Drug Class: ATM inhibitors, ATR inhibitors, DNA methyltransferase inhibitors (launched, pipeline), HDAC inhibitors, PARP inhibitors (branded, generic, pipeline).
  • Mechanism of Action: Monoclonal antibodies, peptides, small molecules (ATM inhibitors, ATR inhibitors, DNA methyltransferase inhibitors, HDAC inhibitors, PARP inhibitors).
  • Indication: Breast cancer (HER2 positive, hormone receptor positive, triple negative), ovarian cancer, pancreatic cancer, prostate cancer.
  • Route of Administration: Intravenous, oral, subcutaneous.
  • End User: Hospitals, pharmacies, specialty clinics.
  • Regions: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: AstraZeneca PLC, Merck & Co., Inc., GlaxoSmithKline plc, Clovis Oncology, Inc., Pfizer Inc.

Key Takeaways

  • Advancements in DNA repair drug modalities are reshaping oncology and rare disease therapeutics, enabling more precise targeting of genomic instability.
  • Stakeholders are leveraging high-throughput screening and molecular biology to identify novel targets, including ATM, ATR kinases, and key epigenetic regulators, fostering a diversified development pipeline.
  • Segmentations by drug class, mechanism, and indication allow drug sponsors to fine-tune clinical investigations, regulatory filings, and commercial strategies around patient needs and regional infrastructure.
  • Growth is being accelerated by improvements in delivery systems—such as nanoparticle encapsulation and targeted conjugates—that improve bioavailability and safety.
  • Integrated diagnostics and companion assay development are increasing therapeutic efficacy, supporting the adoption of precision medicine in real-world settings.

Tariff Impact: Navigating U.S. Policy Shifts in 2025

Revisions to United States tariffs in early 2025 have introduced new pressures on DNA repair drug supply chains. Increased import duties on critical reagents and active pharmaceutical ingredients from global suppliers have prompted leading contract development and manufacturing organizations to localize more production steps. Companies are adapting by dual-sourcing materials, emphasizing robust supplier relationships, and exploring alternative process chemistries to minimize dependency on tariff-exposed sources. Greater visibility in logistics and agile contracting have become essential for maintaining reliable access to essential materials while controlling costs.

Methodology & Data Sources

This research is built on comprehensive secondary analysis, including regulatory filings, clinical trial registries, and industry press releases. Expert insights were gathered through targeted interviews with senior executives and key opinion leaders. Data was cross-validated using triangulation with financial disclosures, patent records, and market transaction documents, augmented by regulatory and tariff policy review. Rigorous confidentiality and integrity protocols ensured unbiased, reliable conclusions.

Why This Report Matters

  • Enables executive teams to identify high-impact growth opportunities and align R&D investments with the latest scientific and market trends.
  • Equips decision-makers with actionable insight into regional variations, regulatory changes, and key competitive dynamics.
  • Supports the formulation of robust commercialization and supply chain resilience strategies tailored to the evolving DNA repair therapeutics landscape.

Conclusion

As DNA repair drug technologies advance, companies that adopt strategic alliances, flexible manufacturing, and patient-tailored approaches will shape the next era of therapeutic innovation. This analysis helps leadership teams navigate shifting market, policy, and clinical landscapes to drive future success in the DNA repair domain.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. DNA Repair Drugs Market, by Drug Class
8.1. Introduction
8.2. Atm Inhibitors
8.3. Atr Inhibitors
8.4. Dna Methyltransferase Inhibitors
8.4.1. Launched
8.4.2. Pipeline
8.5. Hdac Inhibitors
8.6. Parp Inhibitors
8.6.1. Branded
8.6.2. Generic
8.6.3. Pipeline
9. DNA Repair Drugs Market, by Mechanism of Action
9.1. Introduction
9.2. Monoclonal Antibodies
9.3. Peptides
9.4. Small Molecules
9.4.1. Atm Inhibitors
9.4.2. Atr Inhibitors
9.4.3. Dna Methyltransferase Inhibitors
9.4.4. Hdac Inhibitors
9.4.5. Parp Inhibitors
10. DNA Repair Drugs Market, by Indication
10.1. Introduction
10.2. Breast Cancer
10.2.1. Her2 Positive
10.2.2. Hormone Receptor Positive
10.2.3. Triple Negative
10.3. Ovarian Cancer
10.4. Pancreatic Cancer
10.5. Prostate Cancer
11. DNA Repair Drugs Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. DNA Repair Drugs Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Pharmacies
12.4. Specialty Clinics
13. Americas DNA Repair Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa DNA Repair Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific DNA Repair Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AstraZeneca PLC
16.3.2. Merck & Co., Inc.
16.3.3. GlaxoSmithKline plc
16.3.4. Clovis Oncology, Inc.
16.3.5. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DNA REPAIR DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DNA REPAIR DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DNA REPAIR DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DNA REPAIR DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DNA REPAIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DNA REPAIR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DNA REPAIR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. CANADA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. CANADA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. CANADA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. CANADA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 71. CANADA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 73. CANADA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 80. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 82. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 126. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 128. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 135. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 137. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. FRANCE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. ITALY DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. ITALY DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. ITALY DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. ITALY DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 152. ITALY DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 153. ITALY DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. ITALY DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 155. ITALY DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. ITALY DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 161. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 162. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 164. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SPAIN DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. SOUTH AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 197. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 198. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 199. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 200. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. DENMARK DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. QATAR DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. QATAR DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. QATAR DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. QATAR DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. QATAR DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 216. QATAR DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. QATAR DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 218. QATAR DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. QATAR DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 224. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 225. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 227. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. FINLAND DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SWEDEN DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 251. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 252. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 254. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. EGYPT DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 260. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 261. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 263. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. TURKEY DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 278. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 279. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 281. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. NORWAY DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. POLAND DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. POLAND DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 285. POLAND DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. POLAND DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 287. POLAND DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 288. POLAND DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. POLAND DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 290. POLAND DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. POLAND DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. SWITZERLAND DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 311. CHINA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 312. CHINA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 313. CHINA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 314. CHINA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 315. CHINA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 316. CHINA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 317. CHINA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 318. CHINA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. CHINA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. INDIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 321. INDIA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 322. INDIA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 323. INDIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 324. INDIA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 325. INDIA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 326. INDIA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 327. INDIA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. INDIA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 330. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 331. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 332. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 333. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 334. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 335. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 336. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. JAPAN DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2030 (USD MILLION)
TABLE 341. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 342. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 343. AUSTRALIA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 344. AUSTRAL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this DNA Repair Drugs market report include:
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.98 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

DNA Repair Drugs - Global Strategic Business Report - Product Image

DNA Repair Drugs - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
DNA Repair Drugs Market Report 2025 - Product Image

DNA Repair Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
DNA Repair Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

DNA Repair Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Chromatin and Genomic Instability in Cancer. International Review of Cell and Molecular Biology Volume 364 - Product Image

Chromatin and Genomic Instability in Cancer. International Review of Cell and Molecular Biology Volume 364

  • Book
  • Global
DNA Repair in Cancer Therapy - Product Image

DNA Repair in Cancer Therapy

  • Book
  • 330 Pages

About the DNA Repair Drug Market

The DNA Repair Drug market is a subset of the genomics industry that focuses on the development of drugs that can repair damaged DNA. These drugs are used to treat a variety of genetic diseases, including cancer, and can be used to prevent the onset of certain diseases. DNA repair drugs are typically administered through a variety of methods, including intravenous, oral, and topical applications. The DNA Repair Drug market is highly competitive, with a number of companies vying for market share. Companies in the market include AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are actively researching and developing new drugs to treat genetic diseases, as well as exploring new methods of delivery. Additionally, many of these companies are investing in research and development to create more effective treatments for genetic diseases. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.